An uncommon, but very aggressive form of prostate cancer is known as Neuroendocrine prostate cancer (NEPC). It is generally accepted that Circulating Tumor Cell (CTC) counts as measured by CellSearch (a method to catch and count these cells in the blood) are prognostic for most men with metastatic prostate cancer (mPC), but are not well [...]
From: the 2014 ASCO GU Meeting Abstract No: 35 Researchers have found in a randomized controlled trial of men with metastatic castration-resistant prostate cancer (mCRPC) the use of the treatment denosumab was superior to the more commonly used zoledronic acid (ZA) for reducing skeletal-related events (SRE). SREs are defined as a pathological fracture, surgery or [...]
There were many very interesting and very important items presented at the recent ASCO GU conference. Over the course of the next week or two I will be systematically reviewing many of these finds that have a direct impact on men with advanced prostate cancer. Today’s review is about how to create better results for [...]
A John’s Hopkins Health Alert titled “How Long Is It Safe to Take Bisphosphonates for Osteoporosis?” Should Raise Some Concerns Men on Long Term Bisphosphonate Therapy Hormone therapy (ADT) is notorious for many negative side effects, including osteoporosis. Osteoporosis is the thinning of bone that increases the risk for fractures, especially hip and spine fractures. [...]
Based on the assumption that Enzalutamide (Xtandi) is approved for use in men with castrate resistant metastatic prostate cancer (advanced prostate cancer or mCRPC) who have not had prior chemotherapy, pretty much a foregone conclusion based on the extraordinary phase III Prevail Trial results, including a statistically significant survival advantage of 2.2 months with a [...]